| Code | CSB-RA004888MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of FMC63, targeting the CD19 antigen. CD19 is a transmembrane glycoprotein exclusively expressed on B cells throughout their development, from pro-B cells to mature B lymphocytes, but absent on plasma cells. As a critical component of the B cell receptor complex, CD19 functions as a signal transduction molecule that lowers the threshold for B cell activation and regulates B cell proliferation and differentiation. CD19 expression is maintained in most B cell malignancies, including B cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphomas, making it a clinically significant biomarker and therapeutic target.
FMC63 is a well-characterized murine monoclonal antibody that specifically recognizes human CD19. Its single-chain variable fragment serves as the foundation for FDA-approved CAR-T cell therapies, establishing its importance in translational research. This biosimilar reagent enables investigators to study B cell biology, explore CD19-targeted therapeutic strategies, and conduct immunophenotyping studies in hematological research.
There are currently no reviews for this product.